Radiesse vs Sculptra: Which Biostimulator Is Right for You?

Radiesse (Merz; PMA P050052) is an injectable implant whose principal component is synthetic calcium hydroxylapatite (CaHA) — particles of 25 to 45 microns in the 1.5 mL syringe — suspended in a gel carrier of sterile water, glycerin and sodium carboxymethylcellulose.

Merz says Radiesse provides immediate volume correction and also stimulates collagen and elastin production over time.

Sculptra (poly-L-lactic acid, Galderma; PMA P030050) is a different material: Galderma describes it as a biostimulatory injectable that helps stimulate the body's own natural collagen production.

Both are marketed as collagen stimulators, and both hold FDA approvals for facial wrinkles and HIV-related facial fat loss — but they are separate products with separate labels and different approved areas.

Each has its own guide on this site: Radiesse and our Sculptra guide.

Radiesse is the instant-looking one: Merz says it provides immediate volume correction.

Sculptra's label describes the opposite pattern.

The area can look fully corrected right after a session — but the label says that fullness is injection-related swelling, which resolves within several hours to a few days, after which the original depression reappears and correction develops gradually over weeks.

The label builds patience in: the provider should assess the need for additional sessions only after at least four weeks, as the depression improves over several weeks with the treatment effect.

Galderma says results are seen as early as 1 month after treatment.

That is the biggest day-one difference: a correction you see when you leave (per its maker) versus a series of sessions whose effect accumulates.

For the progression vial by vial, see our Sculptra before-and-after guide.

Radiesse's FDA-approved uses are: moderate to severe facial wrinkles and folds such as nasolabial folds (approved 2006-12-22); restoring facial fat loss in people with HIV; volume loss in the back of the hands (2015-06-04); jawline contour for the lidocaine version, Radiesse (+) (2021-09-01); and, diluted 1:2 with saline, décolleté (chest) wrinkles in patients 22 and older (2026-03-31).

That jawline approval makes Radiesse (+) and Juvéderm Volux XC the two US fillers with a jawline indication as of 2026-10-20.

Diluted “hyperdilute” Radiesse has exactly one approved use — that 1:2 dilution for décolleté wrinkles in patients 22 and older.

Neck, arms, thighs, abdomen, knees and buttocks remain off-label — and the 2018 consensus guidelines on diluted CaHA for skin laxity call that body use a “novel off-label use” themselves.

Radiesse is not approved for cheek augmentation, the chin, neck, arms, thighs or buttocks, and its label says safety and effectiveness in the lips and the periorbital (eye) area have not been established.

Sculptra's label indications are shallow to deep nasolabial fold contour deficiencies and other facial wrinkles, fine lines and wrinkles in the cheek region (both in immune-competent people), and facial fat loss in people with HIV.

The cheek indication covers fine lines and wrinkles — not cheek volume or augmentation.

Cheek volume, temples, jawline, chin, under-eyes, lips and body are all off-label for Sculptra — it has no FDA indication for any of them.

Its label bars injection into the red part (vermilion) of the lips, says use in the lips and periorbital area has not been evaluated or studied, and notes superficial injection raises nodule risk.

The sharpest contrast is the jawline: Radiesse (+) holds one of the two US jawline approvals; Sculptra holds none.

Galderma's “86% improved jawline contour at 2 years” is a marketing claim from a study that ended at 96 weeks, not an indication.

Radiesse is priced per syringe, and a syringe is not a fixed size: FDA supplements approved Radiesse syringes of 0.3 cc, 0.8 cc, 1.3 cc and 3.0 cc, and the current label describes a 1.5 mL syringe.

Per-syringe quotes are only comparable if they name the same size, so ask.

Sculptra is measured in vials, not syringes: its label describes 367.5 mg single-patient, single-session vials of powder that must be reconstituted with sterile water before injection.

It is also given as a series: in its trials, patients were treated to optimal correction at 3- or 4-week intervals with a maximum of four sessions.

Session math applies to on-label diluted Radiesse too — in the décolleté trial, each treatment was 1.5 mL diluted with 3.0 mL of saline, given on day 1, week 6 and week 12.

For a national anchor, ASPS lists an average cost of $901 for non-hyaluronic-acid fillers — the group that includes Radiesse and Sculptra — against $715 for hyaluronic acid fillers, per its latest statistics.

Those are physician-fee averages per procedure, not med spa prices and not specific to either product.

We could not find a manufacturer or ASPS per-syringe price for Radiesse, and this page has no product-specific national price for Sculptra beyond that ASPS category average, so treat any quote as the practice's own — and ask what syringe size or vial count, session count and total it implies.

Both makers state the same headline: Merz says Radiesse results “have been shown to last up to 2 years” (citing a 2010 study), and Galderma says Sculptra results last up to 2 years.

Those are manufacturer statements — our research found no head-to-head trial between the two, and “up to” is the top of a range, not what any one person gets.

FDA's general filler page gives estimates by material instead: hyaluronic acid effects last approximately 6 to 12 months, calcium hydroxylapatite approximately 18 months, and poly-L-lactic acid effects may last up to 2 years, appearing gradually over several weeks.

Merz's own safety information is more bounded: it is not known whether Radiesse is safe or effective beyond 3 years in the face, 1 year in the hand and 84 weeks in the décolleté.

Merz lists bruising, redness, swelling, pain and itching as common Radiesse side effects; face studies of Radiesse (+) also reported difficulty chewing, and hand treatments reported nodules or bumps/lumps lasting up to 1 year, difficulty performing activities and loss of sensation.

For Sculptra, the label says common post-injection redness, swelling or bruising typically resolve within hours to one week, with hematoma within about two weeks.

Sculptra's known trade-off is delayed papules and nodules under the skin — usually palpable rather than visible — appearing days to months after injection.

In the US 5-year post-approval study (867 subjects, 5 mL reconstitution), nodules or papules occurred in 28.5% of subjects overall.

The label notes delayed nodules usually appear 3 to 4 months after treatment and may need corticosteroid injection, subcision or excision.

One imaging note is unique to Radiesse: its CaHA particles are radiopaque and can be seen on X-rays and CT scans, so patients should tell their providers and radiologists.

In the décolleté imaging sub-study, no diluted Radiesse was seen on mammograms or breast ultrasounds.

If a result disappoints, there is no enzyme undo for either product.

Hyaluronidase dissolves only hyaluronic acid fillers — not Radiesse (calcium hydroxylapatite), not Sculptra (poly-L-lactic acid).

Sculptra's label lists nodule management options (massage, corticosteroids, saline injection, subcision and surgery) rather than a reversing agent.

Our filler dissolving guide explains how that works for HA filler.

Our research found no label, FDA document or professional guideline addressing Radiesse and Sculptra in one treatment plan, so we can't describe how combined treatment would work, where, or at what intervals.

What the documents do establish: the two products share some on-label territory (smile lines and HIV-related facial fat loss), each covers areas the other does not (hands and jawline for Radiesse; cheek-region fine lines for Sculptra), and they behave differently over time.

Whether a plan should include both is a question for the licensed provider who would do the injecting.

The brand is a real consultation question, because the two differ in material, label and timeline.

Worth settling before you book: which biostimulator the practice recommends for your area, and why; whether that area is on-label for it; how many sessions, syringes (Radiesse) or vials (Sculptra) the plan implies; the syringe size and the per-syringe, per-vial or per-session price; and which licensed provider would do the injecting.

Since neither product has an enzyme undo, it is fair to ask how the practice handles complications.

A provider who answers plainly — including “that area would be off-label for this product” — gives you what this page can only describe generally.